Perhaps targeting the MAPK1 hub-high traffic gene with guanfacine or desipramine may be effective for treating COVID-19 associated comorbidities, such as diabetes, CVDs, and chronic kidney diseases (CKDs) (139). This evidence concerns the gene MAPK1 and chronic kidney disease.